title: Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine.
authors.affiliation: a Division of Hematology, Department of Medicine , University of Alberta , Edmonton , Alberta , Canada.
authors.forename: Lalit
authors.initials: L
authors.lastname: Saini
authors.affiliation: b Department of Medical Oncology , Cross Cancer Institute, University of Alberta , Edmonton , Alberta , Canada.
authors.forename: Neil
authors.initials: N
authors.lastname: Chua
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001374:Azacitidine / Q000009:adverse effects* / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D008279:Magnetic Resonance Imaging; D008297:Male; D009220:Myositis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D016609:Neoplasms, Second Primary; D000077594:Nivolumab; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000911:Antibodies, Monoclonal; D000935:Antifungal Agents; D000077594:Nivolumab; D001374:Azacitidine